The Drug Development Letter

Home
Archive
About
"The landscape of checkpoint inhibitors in oncology" – part 2! Expanding Approvals, Eligibility, and Response
How many patients are eligible for and respond to checkpoint inhibitors? Here is our eagerly awaited updated analysis, now also including the regulatory…
 • 
Alyson Haslam
1
One Arena Where You Can Bend the Rules to Your Advantage: Clinical Trials
Why changing the primary endpoint "target" of a trial is considered a questionable research practice.
 • 
Sahar van Waalwijk
Does the clinical value of a drug predict Medicare expenditures?
In short, the answer is negative, as we found in our study published in the Journal of Cancer Policy. Our analysis also revealed other interesting…
 • 
Ashley Nee
5

December 2024

Analyzing ASCO Tweets: Social Media Trends in Oncology
Our study, published in the Journal of Cancer Policy, delves into the Tweets of researchers identified by the ASCO 2024 organizers as "Featured Voices…
 • 
Owen Stratton
1
Boxing Day Reflections and New Year Resolutions
The tragic story of pregnant women being exposed to an ineffective and potentially unsafe drug
 • 
Sahar van Waalwijk
4
"The landscape of checkpoint inhibitors in oncology" - a portrait of immunotherapy.
In a recent study, we aimed to provide an overview of pivotal clinical trial data supporting the marketing authorization of immune checkpoint…
 • 
Alyson Haslam
3
RANDOMIZED versus REAL-WORLD EVIDENCE ON THE EFFICACY AND TOXICITY OF CHECKPOINT INHIBITORS.
This is a talk I presented at the ESMO Immuno-Oncology 2024 Congress, recorded live with Vinay Prasad and the VKPrasad Lab team, followed by an engaging…
 • 
Timothée Olivier
34:51

November 2024

Can quality of life research learn from restaurant reviews?
𝐖𝐡𝐲 𝐢𝐬𝐧’𝐭 𝐇𝐞𝐚𝐥𝐭𝐡-𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐐𝐮𝐚𝐥𝐢𝐭𝐲 𝐨𝐟 𝐋𝐢𝐟𝐞 (𝐇𝐑𝐐𝐨𝐋) 𝐮𝐬𝐞𝐝 𝐦𝐨𝐫𝐞 𝐨𝐟𝐭𝐞𝐧 𝐢𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞…
 • 
Sahar van Waalwijk
 and 
Susanne Osanto
3
How to design a trial to test the efficacy of Lutetium-PSMA products in metastatic castration-resistant prostate cancer?
This is the response to a comment from a drugdevletter.com follower.
 • 
Timothée Olivier
2
SPLASH - a problematic trial design for an active Lutetium-PSMA product in metastatic castrate-resistant prostate cancer
Presented at ESMO, the compound shows activity; however, the trial design is problematic.
 • 
Timothée Olivier
3
After 23 years, imatinib remains the best front-line therapy in CML. Why use accelerated approval in a setting where patients have a life…
Asciminib - a novel TKI - in Newly Diagnosed Chronic Myeloid Leukemia.
 • 
Timothée Olivier
1
Special post-ESMO 2024 edition !
Timothee Olivier and I discuss the top ESMO 2024 abstracts!
 • 
Vinay Prasad
 and 
Timothée Olivier
1
31:04
© 2025 Vinay Prasad
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture